Tirzepatide

Tirzepatide 15 mg research vial
PHONYX SCIENTIFIC COMPOUND REVIEW

GLP-T2

Catalogue code GLP-T2 identifies a peptide research material documented for laboratory investigation of defined receptor-signalling pathways. Compound identity is provided below for analytical reference.

Purity ≥99%Lyophilized powderDual incretin agonist

The listed format is the total vial content in the PHONYX research portfolio. It is not a weekly clinical dose.

SELECT STRENGTH

Tirzepatide

View Cart
Original price was: 140,00 €.Current price is: 112,00 €.
In stock

For laboratory research only. Not for human consumption.

01 · RESEARCH MATERIAL OVERVIEW

GLP-T2 research material

GLP-T2 is the PHONYX catalogue code for Tirzepatide. The material is presented for laboratory research and analytical reference. Its scientific relevance is based on receptor-binding and signalling characteristics described in the published literature.

The information on this page concerns compound identity, molecular targets and laboratory material specifications. It does not provide administration, dosing, treatment or self-use guidance.

Catalogue codeGLP-T2
Compound identityTirzepatide
CAS No.2023788-19-2
Molecular formulaC225H348N48O68
Approx. molecular mass≈4814 Da
FormLyophilized powder
Available vial content15 mg / 30 mg
CategoryMetabolic Research
02 · MECHANISM

Dual incretin receptor agonism

GIP receptor

GIPR activation supports glucose-dependent insulin secretion and participates in nutrient handling and adipose-tissue signalling. Tirzepatide has comparatively strong activity at this receptor.

GLP-1 receptor

GLP-1R activation supports glucose-dependent insulin secretion, suppresses inappropriate glucagon secretion, reduces appetite and can delay gastric emptying, particularly during treatment initiation.

Integrated effect

Simultaneous activation of both pathways produces a combined metabolic signal affecting glycaemic regulation, satiety and energy intake. The precise contribution of each receptor remains an active research question.

Receptor profile

CompoundGLP-1RGIPRGCGR
Semaglutide✓——
Tirzepatide✓✓—
Retatrutide✓✓✓
08 · PRODUCT SPECIFICATIONS

PHONYX portfolio format

Compound identityTirzepatide
Available formats15 mg / 30 mg
FormLyophilized powder
Purity≥99%
CategoryMetabolic Research
Storage before reconstitutionCool, dry and protected from light
09 · SCIENTIFIC REFERENCES

Evidence behind the key claims

SURPASS-2Frías et al. New England Journal of Medicine, 2021 — tirzepatide versus semaglutide 1 mg in metabolic research. SURMOUNT-1Jastreboff et al. New England Journal of Medicine, 2022 — 72-week metabolic research trial. SURMOUNT-4Aronne et al. JAMA, 2024 — continued treatment versus withdrawal. SURMOUNT-5Head-to-head comparison of tirzepatide and semaglutide in metabolic research. EMA product informationRegulatory pharmacology, dosing, safety and approved indications. ClinicalTrials.gov: SURMOUNT-1Official protocol record for the pivotal metabolic research study.
10 · FAQ

Frequently asked questions

Is tirzepatide the same as semaglutide?

No. Tirzepatide activates both GIP and GLP-1 receptors, whereas semaglutide selectively activates the GLP-1 receptor.

Research Use Only

GLP-T2 (Tirzepatide) is presented exclusively as a laboratory research material. Not for human or veterinary use, consumption or administration. The listed mg values indicate total vial content only and are not dosing instructions. Product information is provided for compound identification, analytical reference and laboratory research context.